Implementation of coordinated global serotype 2 oral poliovirus vaccine cessation: risks of inadvertent trivalent oral poliovirus vaccine use.
about
Maintenance and Intensification of Bivalent Oral Poliovirus Vaccine Use Prior to its Coordinated Global Cessation.Comprehensive screening for immunodeficiency-associated vaccine-derived poliovirus: an essential oral poliovirus vaccine cessation risk management strategy.Monitoring and Validation of the Global Replacement of tOPV with bOPV, April-May 2016.Financial Support to Eligible Countries for the Switch From Trivalent to Bivalent Oral Polio Vaccine-Lessons Learned.Disposing of Excess Vaccines After the Withdrawal of Oral Polio Vaccine.Modeling the costs and benefits of temporary recommendations for poliovirus exporting countries to vaccinate international travelers.The potential benefits of a new poliovirus vaccine for long-term poliovirus risk management.Wild and vaccine-derived poliovirus circulation, and implications for polio eradication.Poliovirus vaccination during the endgame: insights from integrated modeling.Lessons From Globally Coordinated Cessation of Serotype 2 Oral Poliovirus Vaccine for the Remaining Serotypes.Lessons From the Polio Endgame: Overcoming the Failure to Vaccinate and the Role of Subpopulations in Maintaining Transmission.Considerations for the Full Global Withdrawal of Oral Polio Vaccine After Eradication of Polio.Modeling Poliovirus Transmission in Pakistan and Afghanistan to Inform Vaccination Strategies in Undervaccinated Subpopulations.Experience With Inactivated Polio Vaccine Introduction and the "Switch" From Trivalent to Bivalent Oral Polio Vaccine in the World Health Organization's Western Pacific Region.Assessing the stability of polio eradication after the withdrawal of oral polio vaccine.Planning for globally coordinated cessation of bivalent oral poliovirus vaccine: risks of non-synchronous cessation and unauthorized oral poliovirus vaccine use.Polio endgame risks and the possibility of restarting the use of oral poliovirus vaccine
P2860
Q33873406-07AD6576-97B6-4E60-85CE-ADDEA12FC3BFQ37542082-AC50D20D-4822-4884-B304-12BFC5228CD9Q38609807-B16D13EE-069E-4742-A61D-3563F56FD18EQ38637677-52D6B02C-FE3C-4457-A674-03C4084947D2Q38637680-0A2A46A3-1EB0-4569-8836-9FDE877E0E49Q38729183-1147B23A-E4C4-42EA-9A6C-CBF00013B951Q38796753-7DDCAADC-4326-4EFA-A38F-0ED2B3B77484Q39014586-1606A26D-4789-492F-8924-F56852D23B4EQ39258694-90545DF6-1B75-4E90-9E7B-5E3FEEEA3E38Q40071746-0D3A8669-B12A-406F-B001-9A40C0BEC7B0Q40071754-3226494A-3997-40F7-AC88-8632E61870C7Q40071758-62025EDC-6F6B-4F90-A1F0-188216D1DDD7Q47556747-AAFBCD67-D2DD-40E1-A46C-4CCAEC6DC44DQ50496335-7C68A033-DF13-468F-AA1F-7C239BDA50F9Q55114845-DB7CBBEF-A182-4E3A-9B36-06D7009EED91Q55344705-50224301-7B91-49FD-9AE9-DBB7DF7717C7Q58791913-C87167BB-43B8-4D77-802E-337EA4A2799B
P2860
Implementation of coordinated global serotype 2 oral poliovirus vaccine cessation: risks of inadvertent trivalent oral poliovirus vaccine use.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
Implementation of coordinated ...... t oral poliovirus vaccine use.
@ast
Implementation of coordinated ...... t oral poliovirus vaccine use.
@en
type
label
Implementation of coordinated ...... t oral poliovirus vaccine use.
@ast
Implementation of coordinated ...... t oral poliovirus vaccine use.
@en
prefLabel
Implementation of coordinated ...... t oral poliovirus vaccine use.
@ast
Implementation of coordinated ...... t oral poliovirus vaccine use.
@en
P2860
P1476
Implementation of coordinated ...... t oral poliovirus vaccine use.
@en
P2093
Kimberly M Thompson
Lee M Hampton
P2860
P2888
P356
10.1186/S12879-016-1537-8
P577
2016-06-01T00:00:00Z
P6179
1043215734